Reata Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was $502.59 Mil.
During the past 12 months, Reata Pharmaceuticals's average Total Assets Growth Rate was 14.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 91.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 106.30% per year.
During the past 10 years, Reata Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 169.20%. The lowest was -56.50%. And the median was 60.70%.
Reata Pharmaceuticals Total Assets Historical Data
The historical data trend for Reata Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Reata Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reata Pharmaceuticals (NAS:RETA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Reata Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Reata Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Reata Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RETA has been successfully added to your 